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Clinical features of infantile hepatic hemangioendo-
thelioma
Purpose: Infantile hepatic hemangioendothelioma (IHHE) is the most 
common type of hepatic vascular tumor in infancy. We conducted this 
study to review our clinical experience of patients with IHHE and to 
suggest management strategies.
Methods: We retrospectively analyzed the medical records of 23 IHHE 
patients (10 males, 13 females) treated at the Asan Medical Center 
between 1996 and 2009. 
Results: Median age at diagnosis was 38 days (range, 1 to 381 
days). Seven patients (30%) were diagnosed with IHHE based on 
sonographically detected fetal liver masses, 5 (22%) were diagnosed 
incidentally in the absence of symptoms, 5 (22%) had congestive 
heart failure, 3 (13%) had skin hemangiomas, 2 (9%) had abnormal 
liver function tests, and 1 (4%) had hepatomegaly. All diagnoses were 
based on imaging results, and were confirmed in three patients by 
histopathology analysis. Six patients were observed without receiving 
any treatment, whereas 12 received corticosteroids and/or interferon-
alpha. One patient with congestive heart failure and a resectable 
unilobar tumor underwent surgical resection. Three patients with 
congestive heart failure and unresectable tumors were managed by 
hepatic artery embolization with/without medical treatment. At a 
median follow-up of 29 months (range, 1 to 156 months), 21 (91%) 
patients showed complete tumor disappearance or >50% decrease in 
tumor size. One patient died due to tumor-related causes. 
Conclusion: IHHE generally has a benign clinical course with low 
morbidity and mortality rates. Clinical course and treatment outcome 
did not differ significantly between medically treated and non-treated 
groups. Surgically unresectable patients with significant symptoms may 
be treated medically or with hepatic artery embolization.
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Introduction
Hepatic tumors in children are relatively rare, accounting 
for 1 to 4% of all pediatric solid tumors. Infantile hepatic he-
mangioendothelioma (IHHE) is the most common vascular 
tumor of the liver in children, accounting for 12% of all childhood 
hepatic tumors. Almost 85% of patients with IHHE are diagnosed 
during the first 6 months of life, and IHHE is the most common 
symptomatic tumor occurring during this time period. Tumors show 
a female predominance, with a female to male ratio of 1.3 to 2:1
1-6).
The most common chief complaint in patients with IHHE is 
abdominal mass. Other symptoms and signs include hepatomegaly, 
high-output cardiac failure, skin hemangioma, thrombocytopenia, 
hemolytic anemia and peritoneal bleeding. The natural history of 
IHHE varies, but up to two-thirds of symptomatic patients, especially 
those with heart failure and/or jaundice, may die
3,7). 
Although children with asymptomatic lesions may experience 
spontaneous regression within a year, those with symptomatic 
lesions require aggressive management due to the risk of death once 
symptoms commence. The therapeutic options available for these 
patients include both medical and interventional modalities. Medical 
therapy includes treatment with corticosteroids and interferon-alpha 
(INF-α ), whereas interventional modalities include embolization 
and ligation of the hepatic artery, resectional surgery, and liver 
transplantation
1,2,8,9).
Because most previous studies of IHHE are small case series it has 
been difficult to formulate guidelines for the clinical assessment and 
therapeutic approach in patients with IHHE. This study describes the 
clinical features and outcomes of patients with IHHE diagnosed and 
treated over a 14-year period at a tertiary health center and to suggest 
strategies to manage such patients.
Materials and methods
The medical records of 23 patients diagnosed with IHHE at the 
Asan Medical Center between April 1996 and April 2009 were 
analyzed retrospectively. Factors evaluated included gender and age 
at presentation, presenting symptoms, diagnostic procedures, tumor 
location (solitary or multiple), laboratory findings (complete blood 
count, liver function tests [LFTs], thyroid function tests, coagulation 
parameters and alpha-fetoprotein [AFP] concentrations), therapeutic 
modality and treatment outcomes.
Most patients were initially diagnosed by abdominal sonography 
and later evaluated by computed tomography (CT) and/or magnetic 
resonance imaging (MRI), based on the results of sonography. 
Tumors that could not be diagnosed radiologically were examined 
histopathologically. When required, patients with congestive heart 
failure were assessed by echocardiography.
Treatment was based on tumor size and symptom severity, and 
was at the discretion of the treating physician. Patients who were 
asymptomatic and had relatively small tumors were observed or 
treated with corticosteroids and/or interferon-α   (INF-α ). Patients 
with clinical symptoms and unilobar disease were treated by surgical 
resection, whereas symptomatic patients with inoperable tumors 
were treated medically, with or without preceding hepatic artery 
embolization. 
Treatment outcomes were classified as complete resolution, ≥90% 
decrease in tumor size, regression (50 to 90% deczrease), no change 
and progression, with complete resolution and decreasing by 90% 
defined as a major response to therapy.
Results
Twenty-three patients (13 girls, 10 boys) were enrolled; their 
demographic and clinical characteristics at the time of diagnosis 
are summarized in Table 1. Median age at diagnosis was 38 days 
(range, 1 to 381 days), with 18 (78%) patients diagnosed during their 
first 3 months of life, including 7 who were diagnosed by prenatal 
sonography. Median follow-up duration after diagnosis was 29 
months (range, 1 to 156 months). Excluding the seven prenatally 
diagnosed patients and the five asymptomatic patients diagnosed 
incidentally, the main symptoms at presentation were congestive 
heart failure and skin hemangioma. Clinical features on physical 
examination and laboratory findings included hepatomegaly (43%), 
heart failure (30%), abnormal LFTs (22%), increased thyroid-
stimulating hormone (TSH) concentration (22%), coagulopathy 
(11%), and thrombocytopenia (4%). 
Of the 23 patients, 22 were diagnosed by abdominal sonography, 
followed by CT and MRI in 11 patients each; 5 underwent both 
CT and MRI. In three patients, in whom hepatoblastoma could 
not be determined radiologically, the tumors were examined 
histopathologically. Two patients underwent percutaneous biopsy 
of the mass, with findings consistent with IHHE. The other patient 
with heart failure symptoms underwent right partial lobectomy and 
the resected specimen was confirmed as IHHE.
Imaging showed that all 13 patients with single lobe disease had 
solitary lesions (10 in the right and 3 in the left hepatic lobe), whereas 
all 10 patients with bilobar disease had multinodular lesions.
Serum concentrations of AFP were measured in 21 patients and 
shown to be increased for his/her age in 3 (14%). All three patients 
had multiple tumors and were treated by different modalities, but all 
showed complete resolution (Table 2).262      EH Kim, et al. • Infantile hepatic hemangioendothelioma
Six of our 23 patients were observed, with 2 showing major 
response (≥90% decrease in tumor size) after 29 months, and 3 
showing spontaneous regression. One patient showed no change in 
tumor size, but was not treated due to decreased vascularity on follow-
up imaging. Six patients received systemic corticosteroid therapy, 
consisting of a mean dose of 1.9 mg/kg/day of oral prednisolone 
for a median 43 days (range, 15 to 90 days); 3 (50%) successfully 
responded to treatment. All four patients treated with INF-α  showed 
major responses to medical treatment. Two patients were treated with 
a combination of corticosteroids and INF-α .
Interventional modalities included embolization (n=4) and 
conventional resectional surgery (n=1). One patient with Kasabach-
Merritt syndrome (KMS) showed tumor progression despite 
embolization, eventually dying due to coagulopathy, liver failure, 
and sepsis. The other three patients who underwent embolization 
showed partial responses to subsequent corticosteroid or INF-α  (Table 
3). One patient with unilobar disease underwent surgical resection 
due to the persistence of heart failure symptoms; this patient was 
successfully cured without complications associated with surgery. 
Discussion
Though IHHE is the most common hepatic vascular tumor in 
children, it is rarely seen in clinical practice. Over a 14-year period, we 
encountered only 23 patients with this lesion. 
IHHE showed a female predominance, with 13 of the 23 patients 
being girls. Previous studies have reported that the most common 
presenting signs of IHHE are asymptomatic hepatomegaly and 
abdominal mass (50%), followed by cutaneous hemangiomas (10 
to 40%). Extensive arteriovenous shunting may be detected within 
these lesions, resulting in decreased peripheral vascular resistance. The 
maintenance of vascular bed perfusion may require increases in blood 
volume and cardiac output, which may lead to high cardiac output 
and congestive heart failure, observed in up to 50 to 60% of patients 
with IHHE
10-13). 
Hematologic abnormalities may also be present; these include 
including anemia and especially thrombocytopenia caused by 
trapping of thrombocytes within the hemangioendothelioma with 
consumptive coagulopathy (KMS). Less common presentations 
include splenomegaly, jaundice, ascites, gastrointestinal bleeding, 
anemia, feeding difficulties, respiratory compromise, and rarely, 
spontaneous rupture and malignant transformation to angiosarcoma. 
IHHE has also been reported to be associated with fulminant hepatic 
failure and associated biliary atresia
11), deletion of chromosome 
6q
14), heterotopic liver with diaphragmatic hernia
15), trisomy 21, 
transposition of the great arteries, and extranumerary digits
11). 
Of our 23 patients, 14 presented with asymptomatic abdominal 
masses at the time of diagnosis, whereas 5 (22%) were diagnosed 
incidentally without suspicious symptoms. The main complaints at 
Table 1. Patient Demographic and Clinical Characteristics at Diagnosis 
(n=23)
Characteristic Value
Age at diagnosis (mo) 1.3 (0-12.7)
0-3  18 (78)




Median follow-up (mo) 29 (1-156)
Presenting symptom
Fetal sonography 7 
Heart failure 5 
Incidental 5 
Skin hemangioma 3 




Heart failure    7/23 (30)
Abnormal HFT   5/23 (22)
Thrombocytopenia  1/23 (4)
Coagulopathy   2/19 (11)





Biopsy   3
Extent
Solitary (Rt:Lt) 13 (10:3)
Multiple 10
Values are presented as median (range), number (%), or number.
HFT, hepatic function tests; TSH, thyroid-stimulating hormone; CT, 
computed tomography; MRI, magnetic resonance imaging; Rt, right; Lt, left.
Table 2. Tumor Extent and Other Clinical Factors in Three Patients Who 










5.4 Multiple 11,600 US, CT, MRI, Bx PD   42 Resolution
3.2 Multiple 503 CT, US, Bx IFN 126 Resolution
2.4 Multiple 37,700 US, CT No   29 Resolution
Tx, treatment; F/U, follow-up; US, ultrasonography; CT, computed tomo-
graphy; MRI, magnetic resonance imaging; Bx, biopsy; PD, prednisolone; 
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presentation were heart failure, skin hemangioma, hepatomegaly, and 
abnormal LFT results. Physical examination revealed hepatomegaly 
in 10 (43%) patients. Detailed physical examination is usually 
needed for accurate assessment. About half of our patients with 
IHHE had high output heart failure, considered a leading cause of 
death, along with consumptive coagulopathy. In addition, increased 
serum TSH concentrations were observed in two of the nine patients 
tested. Clinically significant hypothyroidism may be due to thyroid 
hormone catabolism by the tumor
16), indicating the need for thyroid 
function tests in patients suspected of having IHHE. We found, 
however, that the incidences of hepatosplenomegaly and abdominal 
mass, previously reported to be the most common presenting signs in 
patients with IHHE, were lower than previously reported. In contrast 
to previous reports however, tumors in many of our patients were 
detected by fetal sonography and few had clinically severe conditions. 
Thus, high proportion of the patients with incidentally detected 
IHHE may explain the reduced incidence of patients with clinically 
severe IHHE.
In addition, because more patients may be diagnosed prenatally, 
further studies may be needed to assess the natural history and 
treatment strategy of IHHE during the neonatal period. 
Radiological evaluation is useful for patient diagnosis, with 
sonography often being the initial diagnostic modality. On sono-
graphy, IHHE is characterized by discrete, hypoechoic lesions (either 
solitary or multiple) within the liver that may have calcifications or 
shunting on Doppler evaluation.
 Of our 23 patients, 22 were diagnosed by sonography including 
7 who were diagnosed by fetal sonography. Compared with 
sonography, CT shows a more variable enhancement pattern, 
although it offers several advantages, including more precise 
anatomical localization, tissue enhancement and characterization
17, 
18). MRI generally shows well-defined spherical lesions, hypointense 
to the liver on T1 sequences and hyperintense on T2, with flow-
voids and centripetal enhancement after the administration of 
gadolinium
17, 19). However, it may be difficult to establish a definite 
diagnosis based on imaging modalities alone. Histopathologically, 
IHHEs are usually composed of vascular channels lined by a single 
continuous layer of plump endothelial cells in a supporting fibrous 




Lesions Presenting Sx Indication Tx modality
Tx duration 
(mo)*
F/U duration   
(mo)
Outcome
1 F 9 Solitary (Rt)  Abnormal HFT No 4 In regression
2 F 9 Solitary (Rt)  Incidental No 15 In regression
3 M 0 Solitary (Rt)  Prenatal No 6 No change
4 F 3 Multiple Skin hemangioma No 29 >90%
5 F 2 Multiple Abnormal HFT No 29 Resolution
6 F 1 Solitary (Rt)  Incidental No 10 In regression
7 F 13 Multiple Incidental Multiple PD 1.6 mg/kg/day 1.8 / 3.9 12.5 In regression 
8 F 5 Multiple Hepatomegaly Multiple PD 1.6 mg/kg/day 1.9 / 4.2 41.8 >90% 
9 M 1 Solitary (Rt)  Incidental Huge mass PD 2.4 mg/kg/day 0.5 / 3.5 30.4 In regression 
10 F 0 Solitary (Rt)  Prenatal Huge mass PD 1.7 mg/kg/day 1.0 / 2.4 22.9 Resolution 
11 M 3 Multiple Skin hemangioma Multiple PD 1.4 mg/kg/day 3.0 / 4.0 37.7 Resolution 
12 M 0 Solitary (Lt)  Prenatal Early CHF PD 1.9 mg/kg/day 0.5 / 1.4 6.1 In regression
13 M 1 Multiple Skin hemangioma Huge mass IFN-α 5.9 20 >90%
14 F 3 Multiple CHF CHF IFN-α 6.7 126 Resolution
15 F 9 Solitary (Rt)  Incidental CHF IFN-α 5.2 35 Resolution
16 M 0 Solitary (Rt)  Prenatal Huge mass IFN-α 5.6 49 >90%
17 M 1 Solitary (Rt)  CHF CHF IFN-α + PD 4.2 46 In regression
18 F 1 Multiple CHF CHF IFN-α + PD 5.5 48 >90%
19 F 0 Multiple Prenatal CHF, KMS Embolization NA 1 Progression
†
20 F 0 Solitary (Lt)  Prenatal CHF PD → Emb 6.3 156 In regression
21 M 0 Solitary (Lt)  Prenatal Huge mass, early CHF Emb → PD 2.7 5 In regression
22 M 1 Multiple CHF CHF Emb→ IFN-α 5.6 57 In regression
23 M 3 Solitary (Rt)  CHF CHF Lobectomy NA 56 Resolution
Sx, symptoms; Tx, treatment; F/U, follow-up; Rt, right; Lt, left; HFT, hepatic function test; CHF, congestive heart failure; KMS, Kasabach Merritt syndrome; PD, 
prednisolone; IFN-α, interferon-alpha; Emb, embolization; NA, not available.
*Tx duration: full dose / tapering. 
†Progression to coagulopathy, liver failure and sepsis despite embolization in 1 patient.264      EH Kim, et al. • Infantile hepatic hemangioendothelioma
stroma that may contain well-preserved bile ducts. Hematopoietic 
activity is a specific characteristic of these tumors. Thrombosis with 
infarction, followed by fibrosis and even calcification, can occur in 
the centers of large tumors
8,20).
Serum AFP is an important tumor marker for the evaluation of 
pediatric hepatic masses. Serum AFP concentrations decrease rapidly 
after birth and reach adult levels by 8 months of age. Increased serum 
AFP concentrations are rarely observed in patients with IHHE, 
with one study reporting that clinical symptoms, age at presentation, 
tumor size and AFP concentration were not significantly related 
to time required for complete tumor regression
21-23). Similarly, only 
three of our patients had increased concentrations of AFP, with all 
three having multiple tumors; despite receiving different treatment 
modalities, all three showed nearly complete tumor resolution. 
We found, however, that increased AFP was not directly related to 
treatment outcome. The etiology of increased serum AFP in IHHE 
is unclear, but it may be secreted by morphologically normal hepatic 
cells in response to the tumor
5,22). AFP was shown to be expressed 
by hepatocytes near or trapped within the tumor, but not by tumor 
cells
23).
The most important prognostic factors are the presence of a 
symptomatic mass, congestive heart failure, jaundice, and multiple 
tumor nodules, and the absence of cavernous differentiation
3-5,7).
Not all patients with IHHE require treatment. These tumors 
tend to grow during the first year of life then spontaneously regress 
without treatment, probably due to thrombosis and scar formation. 
The decision not to treat asymptomatic patients is not a strict rule. 
Each patient should be evaluated individually. Indications for therapy 
may include cardiac insufficiency, respiratory distress, coagulopathy, 
abdominal compartment syndrome and deterioration in hepatic 
function tests. If therapy is needed, first-line medical treatment is 
recommended, followed in some patients by invasive or surgical 
procedures
3,5,7,9).
Among the medical treatments for these tumors are corticosteroids, 
cytotoxic agents, INF-α , and irradiation. Patients who do not respond 
to medical treatment may undergo radical interventions, such as 
hepatic artery ligation, transcatheter hepatic artery embolization, 
surgical resection, and even liver transplantation
24). Surgical resection 
is recommended to remove huge masses with a low potential 
for spontaneous regression and masses for which a diagnosis of 
malignancy cannot be excluded clinically and/or radiologically
25-27).
Spontaneous resolution occurred in 2 of 6 asymptomatic patients 
without specific therapy (33%), and 8 (67%) of 12 patients were 
successfully treated with corticosteroids and/or INF-α . Of patients 
Table 4. Outcomes Relative to Management in Patients with Infantile Hepatic Hemangioendothelioma (n=23)
Observation (n=6) Steroid (n=6) IFN (n=4) Steroid/IFN (n=2) Embolization (n=4) Op (n=1) No. (%)
Progression 0 0 0 0 1 0 1 (4)
No change 1 0 0 0 0 0 1 (4)
Regression 3 3 0 1 3 0 10 (43)
≥90% Decrease 1 1 2 1 0 0 5 (22)
Resolution 1 2 2 0 0 1 6 (26)
IFN, interferon; Op, operation.
Fig. 1. Management strategy for patients with infantile hepatic hemangioendothelioma (IHHE). 
Dx, diagnosis; Op, operation.Korean J Pediatr 2011;54(6):260-266 • DOI: 10.3345/kjp.2011.54.6.260    265
treated with corticosteroids alone, 50% achieved resolution of the 
lesion, similar to previously reported response rates as high as 45% in 
symptomatic patients
8). Responses often occurred within 1 or 2 weeks 
and a median time to complete resolution by medical treatment was 
approximately 30 months (range, 0 to 43 months). Although the 
precise mechanism of action is unclear, corticosteroids may cause 
vasoconstriction of the rapidly proliferating immature endothelial 
cells that line the vascular channels of the lesion
3). Moreover, the 
antiangiogenic agent INF-α , which inhibits endothelial cell migration 
and proliferation, may also be helpful in causing early regression of 
hemangioendotheliomas resistant to corticosteroids
28). We also found 
that INF-α  yielded satisfactory results, either alone or in combination 
with steroids. Embolization was effective in three patients who had 
inoperable, symptomatic, and solitary lesions, but was not successful 
in one patient despite additional therapy (corticosteroids, INF-α ) 
(Table 4). We found that 48% of patients with IHHE could be 
managed successfully with or without treatment, with tumor 
regression observed in an additional 43%.
Based on our experience and the current literature, we propose the 
following algorithm for the treatment of children with IHEE (Fig. 1). 
Once the diagnosis is suggested, either by patient symptomatology 
or as an incidental finding, prompt diagnostic evaluation is 
mandatory. Asymptomatic unilobar lesions may be observed for 
regression. However, both asymptomatic, but progressive lesion and 
symptomatic lesions should be treated with corticosteroids and/
or INF-α . If, despite medical treatment, symptoms progress over 
several weeks or develop in patients with asymptomatic lesions, 
interventional modalities should be used immediately. If the lesion 
is accessible to surgical resection, partial hepatectomy should be 
performed as definitive therapy. Patients with inoperable tumors 
should undergo embolization followed by medical therapy, either to 
attempt a definitive cure or as a temporary measure while the patient 
is evaluated and listed for cadaveric orthotopic liver transplantation or 
until a suitable living, related donor is identified.
Given the malignant potential of IHHEs, we recommend long-
term monitoring of patients with presumed or confirmed IHHE, 
at least until complete resolution of the hepatic lesion. Monitoring 
is probably best accomplished by serial clinical examinations and 
imaging with sonography or CT. Serum AFP concentration should 
also be monitored if it was increased at the time of diagnosis. 
Patients with IHHE usually have an excellent prognosis, especially 
because the rates of spontaneous regression after the first year of life 
and long-term survival are about 70%. A multidisciplinary approach 
that involves pediatric oncologists, radiologists and surgeons is the 
best treatment option for these patients, increasing their survival.
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